Trial Profile

24-wk Efficacy and Safety of Flibanserin vs Pbo in Naturally Postmenopausal Women in United States.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Flibanserin (Primary)
Indications Decreased libido; Female sexual dysfunction
Focus Therapeutic Use
Acronyms SNOWDROP
Sponsors Sprout Pharmaceuticals

Most Recent Events

25 Sep 2021 Results of post-hoc analysis onset of flibanserin's treatment effect in naturally postmenopausal women with HSDD across the 6 subdomains of the FSFI, presented at the North American Menopause Society 2021 Annual Meeting.
16 May 2017 Results of a post-hoc analysis from three 24-week trials presented at the 112th Annual Meeting of the American Urological Association
02 Mar 2012 Company added in the association field as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com